Efficacy of Azithromycin Injection Combined with Levofloxacin Capsule and Ambroxol Injection in the Treatment of Mycoplasma Pneumonia

Abstract

Objective: To investigate the clinical efficacy and safety of combining azithromycin injection with levofloxacin capsule and ambroxol injection for the treatment of Mycoplasma pneumonia. Methods: A total of 160 cases of patients with mycoplasma pneumonia were randomly assigned to either the control group or the experimental group, with 80 cases in each group. In the control group, azithromycin injection was administered at a dosage of 10 mg/kg once daily via intravenous drip. The experimental group received treatment based on the control group regimen, supplemented with levofloxacin capsules at a dosage of 0.2 g (2 capsules) twice daily and ambroxol injection at a dosage of 1.2-1.6 mg/(kg.d), given 2-3 times per day through slow intravenous injection lasting for 2-3 minutes. Both groups underwent a treatment duration of 7 days. Clinical efficacy, antipyretic time, cough extinction time, lung rales extinction time, and adverse drug reactions were compared between the two groups. Results: The test group exhibited an effective treatment rate of 88% for mycoplasma pneumonia, whereas the control group was 74%. The test group demonstrated significantly shorter durations for fever, cough, and lung rale disappearance compared to the control group. Conclusion: The combination of azithromycin, levofloxacin, and ambroxol significantly enhances the efficacy in treating mycoplasma pneumonia. It can further shorten improvement signs and has high safety. It is worth application for non-pediatric patients with mycoplasma infection.